Induction of a senescent phenotype in tumor cells has been linked to anticancer immune response, however, the molecular mechanisms mediating these phenomenon have not yet been determined. In this study, we present evidence that induction of premature senescence in human cancer cell lines induces Fas expression, and loss of resistance to Fas-induced apoptosis. Triggering of Fas by using the agonistic antibody CH11 or the recombinant ligand APO010, activates an apoptotic pathway responsible for cell death. Secretion of pro-inflammatory cytokines by the senescent cells, particularly TNF-a and IFN-c, mediates Fas upregulation. Indeed, treatment of proliferating cancer cell lines with TNF-a and IFN-c, upregulates Fas expression, while blocking TNF-a and IFN-c by using neutralizing antibodies, decreases Fas expression in senescent cells. We also demonstrate that NF-jB has a central role in controlling the senescence-associated secretory phenotype (SASP) by the premature senescent cells, and that TNF-a and IFN-c, transcriptionally controlled by NF-jB, are the main mediators of Fas upregulation. Our data suggest the existence of an NF-jB-dependent autocrine loop, mediated by TNF-a and IFN-c, responsible for expression of Fas on the surface of senescent cells, and for their killing.
Introduction
Replicative senescence was described in normal cells as an intrinsic molecular program that limits cell multiplication (Hayflick and Moorhead, 1961) . Telomeric attrition activates a DNA damage response, which triggers a permanent, irreversible cell-cycle arrest. Senescent cells remain viable, metabolically active and acquire distinctive morphological and biochemical alterations, such as the expression of acidic b-galactosidase (SA-b-gal). Apart from aging, several different stimuli can trigger senescence in normal human cells. For instance, oncogene activation in normal cells induces a permanent proliferative arrest termed oncogene-induced senescence, which functions as a barrier to cell transformation (Braig and Schmitt, 2006; Bartek et al., 2007) . Although cancer cells bypass both replicative and oncogene-induced senescence, the genetic program of senescence in these cells seems to be repressed, but not lost, in such a way that it can be reactivated by expression of critical regulators. Accordingly, restoration of senescence regulatory pathways in tumor cells rapidly elicits senescence (Wang et al., 1998 (Wang et al., , 1999 . In addition, a process termed stress-induced or premature senescence can be readily elicited in tumor cells by treatment with sublethal concentrations of conventional anticancer drugs (Chang et al., 1999) . Premature senescence is a major cellular response to chemotherapy and radiotherapy in solid tumors, both in vitro and in vivo (te Poele et al., 2002; Mirzayans et al., 2005) , and the induction of a senescent-like phenotype by anticancer drugs was shown to be one of the key determinants of tumor response to therapy in vitro and in vivo (Schmitt et al., 2002) .
Induction of a senescent phenotype in tumors has been linked to anticancer immune response (Ventura et al., 2007; Xue et al., 2007) . For instance, restoration of endogenous p53 expression in hepatocarcinoma and sarcomas leads to induction of a senescence program that triggers an innate-immune response and in vivo tumor clearance (Ventura et al., 2007; Xue et al., 2007) . Molecular mechanisms mediating these anticancer immune responses have not yet been determined, although several studies demonstrate that inflammatory cytokines and immune modulators are upregulated in senescent cells (Raulet and Guerra, 2009 ). For instance, it has recently been shown that multiple myeloma senescent cells upregulate NK-and T-cells ligands. Expression of these ligands depends on the DNA damage response (Gasser and Raulet, 2006; Soriani et al., 2009) . Notably, the DNA damage response also regulates the expression of death receptors in tumor cells, in response to ionizing radiation or chemotherapy (Raulet and Guerra, 2009) .
Recent evidence has shown that acquisition of a senescent phenotype, both in fibroblasts and in epithelial cells, is accompanied by a specific increase in the secretion of cytokines, chemokines and other factors, which affect both senescent cells and neighboring cells, via autocrine/paracrine signaling (Young and Narita, 2009 ). Secretion of these factors has been termed the 'senescence-associated secretory phenotype' or SASP. SASP develops gradually, coincident with acquisition of a fully senescent phenotype, and varies with both the cell type and the agents used to induce senescence. Notably, SASP occurs not only in cultured cells, but also in vivo in response to DNA-damaging chemotherapy (Coppeé t al., 2008) . SASP mediates a crosstalk between senescent cells and the surrounding microenvironment and could have different effects. For instance, some of the proteins secreted by senescent cells stimulate angiogenesis and promote growth and invasion of neighboring cancer cell (Coppe´et al., 2010; Freund et al., 2010) . On the other hand, the SASP has at least two beneficial roles: factors secreted by senescent cells function in an autocrine manner to reinforce the senescence growth arrest (Acosta et al., 2008; Kuilman et al., 2008; Wajapeyee et al., 2008) , and the SASP stimulates clearance of senescent cells by NK cells (Krizhanovsky et al., 2008) . Most components of SASP are transcriptionally regulated by the transcription factors NF-kB and C/ EBPb (Acosta et al., 2008) . NF-kB is a family of transcription factors, the biological functions of which, namely inflammation, immunity, apoptosis, cell-cycle progression and stress response are all altered during senescence (Vallabhapurapu and Karin, 2009 ). There are two distinct NF-kB activation pathways, termed the canonical and the alternative (aka non-canonical) NFkB pathways. Briefly, the canonical NF-kB pathway, which is activated by inflammatory cytokines and stress pathways, leads to the degradation of the inhibitory subunit IkB, and to the nuclear accumulation of the RelA/p50 and c-Rel/p50 dimers (Ha¨cker and Karin, 2006) . The alternative NF-kB pathway is activated by a selected group of members of the TNF receptor family such as CD40 and BAFF receptor (Ha¨cker and Karin, 2006) . Activation of this pathway leads to the processing of p100 to produce p52, which forms heterodimer with RelB (Naumann et al., 1993) . The canonical pathway controls transcription of genes involved in innate and adaptive immune responses, while the alternative pathway mainly controls secondary lymphoid organ development and lymphocytes survival. Recently, the NF-kB canonical pathway has been implicated in maintaining senescent growth arrest in normal cells (Adler et al., 2007) . This evidence points to NF-kB as one of the major candidate in the induction, establishment and/or maintenance of cell senescence, as well. In this study, we show that NF-kB modulates the SASP of drug-induced tumor senescent cells. By increasing the expression of inflammatory cytokines (that is, TNF-a and IFN-g), NF-kB triggers a positive feedback loop that increases expression of Fas and sensitizes senescent tumor cells to Fas-mediated apoptosis.
Results

Fas upregulation in senescent tumor cells
Numerous evidence 'in vivo' suggest that senescent cells signal to the immune system to promote their own clearance. To investigate the crosstalk between senescent cells and cells of the immune system, and the molecular mechanisms regulating clearance of the senescent cells, we induced senescence in the lung and breast cancer cell lines A549 and MCF7, and evaluated expression of different death receptors. A characterization of the two cell lines is illustrated in Supplementary Figure 1 . Both cell lines showed morphological alterations, SA-b-gal staining, and cell-cycle distribution typical of premature senescent cells. We evaluated the expression of Fas, DR4 and DR5 on proliferating and senescent A549 and MCF7 cells. Induction of senescence in both tumor cell lines was associated with a decrease in DR5 and an increase in Fas expression, as assessed by flow-cytometric analyses (Figure 1a ). Both the percentages of Fas-positive cells and the mean fluorescence intensity (MFI) were significantly increased in senescent cells as compared with the proliferating counterparts ( Table 1) . Upregulation of Fas protein on senescent cells was also confirmed by immunofluorescence (Figure 1b) . Real-time PCR analyses showed that Fas mRNA was increased in senescent tumor cells, as compared with the proliferating ones, suggesting that the increased expression of Fas was due to 'de novo' gene transcription ( Figure 1c ). DR4 protein was undetectable on both proliferating and senescent cells (data not shown).
Loss of resistance to Fas-induced apoptosis in senescent tumor cells To investigate the effects of Fas upregulation in senescent tumor cells, proliferating and senescent MCF7 and A549 cells were treated with the anti-Fas agonistic antibody CH11. As shown in Figure 2 , senescent cells readily undergo apoptosis, as judged by MTT assay and caspase-8 activation, while proliferating cells were completely resistant to CH11 antibody. To further demonstrate that Fas was mediating apoptosis of senescent cells, we stimulated them with different concentrations of APO010, a humanized, recombinant mega-CD95L that shows anticancer activity in vitro and in animal models (Verbrugge et al., 2009; Russo et al., 2010) , and is currently in a phase I trial in patients with solid tumors (http://ClinicalTrials.gov identifier: NCT00437736). Cell viability was assessed after 24 and 48 h. As shown in Figure 2) . These data indicate that induction of premature senescence in tumor cells is associated with selective loss of resistance to Fas-mediated apoptosis.
SASP mediates Fas upregulation
Acquisition of a fully senescent phenotype takes several days to establish, and is associated with the development of a SASP (Coppe´et al., 2008) . Senescent cells secrete cytokines and other factors that affect senescent cells, as well as neighboring cells, via autocrine/paracrine signaling (Freund et al., 2010) . As inflammatory cytokines induce Fas expression in different cell types (Kimura et al., 2003; Fluhr et al., 2007) , we wondered whether upregulation of Fas in senescent tumor cells was dependent on SASP. To identify secreted factors produced by premature senescent tumor cells, we measured cytokine/chemokine in conditioned media from proliferating and senescent MCF-7 cells, using a 30-plex cytokine assay. As shown in Table 2 , compared with the proliferating counterpart, senescent cells showed increased secretion of several cytokines and chemokines. In line with a gradual development of Among cytokines, TNF-a and IFN-g have been show to synergistically induce Fas expression in stromal endometrial cells (Fluhr et al., 2007) . In agreement with these data, combined treatment with TNF-a and IFN-g, readily upregulated surface Fas on proliferating A549 cells (Figure 5a ), and proliferating MCF-7 cells ( Figure 5b ). In addition, the use of neutralizing Antibodies anti-TNFa and IFN-g receptor alpha on senescent cells, reduced expression of Fas ( Figure 5c ).
NF-kB modulates SASP and Fas expression
Recent studies identified NF-kB as regulator of the SASP (Acosta et al., 2008) . In addition, a crucial role for NF-kB in induction of Fas expression has been demonstrated (Ouaaz et al., 1999; Ku¨hnel et al., 2000) . To identify which components of secretory phenotype are modulated by NF-kB in premature senescent tumor cells, we knocked-down expression of RelA, the main member of the NF-kB family, in MCF-7 and A549 cells by using lentiviruses encoding small hairpin RNA. A partial characterization of the interfered MCF-7 cells (indicated thereafter as M2), and interfered A549 cells (indicated as A2) is illustrated in Supplementary Figure  3 . Western blotting showed significant silencing of RelA in both M2 and A2 cells, as compared with scramble infected controls (MSCR and ASCR, respectively). In addition, TNF-a-induced NF-kB-dependent luciferase activity was significantly reduced in RelA-interfered cells. Expression of other members of the NF-kB family was not affected (data not shown). Thereafter, we analyzed the conditioned media from scramble-and RelA-interfered MCF-7 cells, using a 30-plex cytokine assay. As shown in Table 2 , senescent MSCR cells showed a secretion profile fully comparable to that of the parental MCF-7 senescent cells. Interestingly, secretion of several cytokines and chemokines was significantly reduced in RelA-interfered M2 cells (in bold in Table 2 ). Some of the differences were validated by quantitative real-time PCR in RelA-interfered A549 cells ( Figure 6 ). Notably, secretion of both TNF-a and IFN-g seemed to be modulated by RelA. Hence, we investigated if the reduced secretion of TNF-a and IFNg, in RelA-interfered cells, results in reduced Fas expression upon senescence induction. Indeed, both M2 and A2 senescent cells showed lower surface Fas protein as compared with relative scrambled controls (Figure 5d ). To further demonstrate that TNF-a and IFN-g modulated Fas expression via NF-kB, we stimulated proliferating Rel-A interfered cells and control cells with TNF-a and IFN-g, and analyzed surface Fas after 24 h. As shown in Figures 5e and f, 
Discussion
In the present manuscript we show that induction of senescence in tumor cells results in increased expression of Fas, and in loss of resistance to Fas-induced apoptosis. Fas upregulation upon senescence induction is mediated by TNF-a and IFN-g, as stimulation of proliferating cells with these two cytokines results in increased Fas expression, while blocking TNF-a and IFN-g by using neutralizing antibodies, decreases Fas expression in senescent cells. We also demonstrate that NF-kB has a central role in regulating both Fas expression, and cytokine and chemokine secretion in senescent cells, as 'NF-kB null' senescent cells showed decreased expression of TNF-a and IFN-g (in addition to other cytokines and chemokines), and decreased expression of Fas. Cellular senescence is a state of irreversible proliferative arrest caused by different stresses, such as DNA damage and activation of certain oncogenes, which are potentially deleterious for the cells. It may be seen as a tumor suppressive mechanism that prevents in vivo tumor progression. In fact, senescence is an active state, in which cells express a number of genes products of which function in an autocrine and paracrine way to reinforce senescence, and then to keep the damaged cells in a non-proliferative state, and to clear the senescent cells themselves. Our data extend this notion by identifying TNF-a and IFN-g, produced and secreted by the senescent cells, as the molecular signals functioning in an autocrine manner to increase expression of Fas, likely favoring killing of senescent cells by activated immune effector cells, capable of expressing FasL. Thereafter, the cytokines and chemokines produced by senescent cells (see Table 2 ), not only orchestrate the recruitment of cells of the immune system (Xue et al., 2007) , but also induce their own clearance. Indeed, we have evidence that, at least 'in vitro', senescent cells recruits monocytes and are actively killed by them (EC and AL unpublished observation). On the other hand, recruitment of inflammatory cells may represent a selective advantage for cancer cells not undergoing senescence after treatment with chemotherapeutic drugs, establishing a microenvironment that favors tumor growth. This may explain why, in different experimental systems, premature senescence may have deleterious effects, such as increased angiogenesis and tumor growth and invasion, or beneficial effects, such as tumor clearance. Supporting this hypothesis is the notion that two of the major pro-inflammatory cytokines secreted by senescent cells, IL-6 and IL-8, may function either to reinforce senescence (Kuilman et al., 2008) or to promote tumor invasiveness (Coppe´et al., 2008) . Thereafter, regulation of the inflammatory environment 
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may have a critical role in determining the fate of both senescent and proliferating tumor cells.
Senescent human fibroblasts express high levels of intracellular and membrane bound form of IL-1a, but not the soluble form. Membrane bound IL-1a has been demonstrated to be a key component of the SASP, as it positively regulates IL-6 and IL-8 expression, functioning by sustaining NF-kB and c/EBP activation (Orjalo et al., 2009) . In agreement with these data, we have been unable to detect soluble IL-1a and b in the conditioned media of senescent cells (Table 2 and data not shown). In addition, in our experimental system, senescent cells secrete, in a NF-kB-dependent manner, IL-1RA a soluble competitor of the IL-1 receptor (Table 2) , the function of which is to compete with IL-1 for binding to the receptor to prevent excessive inflammation. This observation suggest that IL-1 production and function needs to be tightly controlled: by localizing IL-1 on the membrane of senescent cells to regulate secretion of pro-inflammatory cytokines IL-6 and IL-8, and by secreting IL-1RA to block potential paracrine effect of IL-1. It is also worth noting that in the absence of functional NF-kB, the amount of secreted IL-8 drops at the level of proliferating cells, thus confirming the absolute requirement of NF-kB for IL-8 production. IL-6 secretion is not affected by the loss of NF-kB, suggesting that other signaling pathways, for instance c/EBP, are involved in SASP.
How is activation of NF-kB mediated in senescent cells? This question is still unanswered. We have evidence that, at least in our experimental system, 
development of a fully senescent phenotype is associated with a progressive inactivation of the DNA damage response (estimated by scoring g-H2AX foci), while NF-kB activation (indirectly assessed by measuring cytokines expression) gradually increases (Supplementary Figure 4 ). It is possible that NF-kB activation is initiated by DNA-damage via ATM and NEMO sumoylation (Huang et al., 2003) , and then proceeds via an autocrine loop, sustained by the pro-inflammatory cytokines produced by the senescent cells. NF-kB activity seems not to be indispensable for senescence induction. In fact, induction of senescence following treatment with DNA-damaging agents is not affected in RelA-interfered cells. Interestingly, NF-kB seems to be involved in maintenance of senescence. In fact, in the RelA interfered cells, we observed increased 'senescence escape' (data not shown). As secreted proteins have a critical role in the maintenance of some forms of oncogene-induced senescence (Acosta et al., 2008; Kuilman et al., 2008; Wajapeyee et al., 2008) , it is tempting to speculate that altered SASP profile in RelAinterfered cells might affect maintenance of senescence in tumor cells. We are currently investigating whether the observed senescence escape is due to the altered SASP profile (for example loss of IL-8 secretion), or other factors, such as the increased genomic instability observed in the absence of functional NF-kB (Wang et al., 2009 ).
Our data increase our understanding of how SASP is controlled at transcriptional level. It has been demonstrated that NF-kB and C/EBP are required for the transcription of many SASP factors (Freund et al., 2010) , and our data confirm the requirement of NF-kB for the transcription of many SASP components, and also provide a functional consequence of the absence of functional NF-kB. The decreased expression of TNF-a and IFN-g in the NF-kB null cells interrupts the autocrine loop responsible for expression of Fas on the surface of senescent cells, and for their killing.
Tumor cells develop multiple mechanisms to evade Fas-induced apoptosis, by inhibiting Fas signaling at several levels. A common mechanism to acquire resistance to Fas-mediated apoptosis is to downregulate Fas (Houston and O'Connell, 2004) . In this study we show that senescence induction upregulates Fas expression and that triggering of Fas, by using agonistic antibody CH11, results in the activation of the apoptotic pathway and killing of senescent tumor cells. This is in agreement with data showing that the amount of Fas receptors determines the cell-death rate, and that quantitative increases in Fas expression above a certain threshold level results in sensitivity to Fas-mediated apoptosis (Neumann et al., 2010) . We also show that pharmacological modulation of the Fas pathway might be used to effectively target senescent tumor cells. Triggering of Fas by using APO010, readily induces NF-jB controls Fas levels on senescent tumor cells E Crescenzi et al cell death in senescent tumor cells. As tumor cells treated with DNA-damaging chemotherapeutic drugs and/or radiotherapy, undergo senescence, it is tempting to speculate that it would be possible to increase cell death after therapy by using molecules, such as APO010, that target Fas pathway. 
Materials and methods
Cell culture and biological reagents A549 cells were obtained from American Type Culture Collection (Teddington, UK) and cultured according to its instructions. MCF-7 cells were cultured in DMEM. All media were supplemented with 10% fetal bovine serum. The cell culture media and reagents were purchased from Invitrogen (San Giuliano Milanese, MI, Italy). Doxorubicin (Merck Chemicals, Nottingham, UK) was dissolved in sterile water. Camptothecin (Sigma, Milano, Italy) was dissolved in DMSO.
The anti-Fas-PE (CD95; 555674) and anti-TRAIL-PE (CD-253; 550516) antibodies were purchased from BD Biosciences (Erembodegem, Belgium); anti-DR5 (CD262) and DR4-Alexa Fluor488 (CD261) were purchased from AbD Serotec (Oxford, UK); anti-Fas agonistic antibody CH11 (05-201) from Millipore (Billerica, MA, USA). The anti-TNF-a neutralizing antibody (552467) and the anti-IFN-gRa neutralizing antibody (CD119, 557531) were purchased from BD Biosciences. The anti-p65 (C-20) and anti-Actin (I-19) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). APO010, a recombinant humanized Fas-ligand, was kindly provided by TopoTarget A/S, Copenhagen, Denmark.
Induction of premature senescence and senescence-associated b-galactosidase (SA-b-gal) activity Unless otherwise stated, senescence was induced by treating cells with the DNA-damaging agents doxorubicin (200 nM for MCF-7 cells and 600 nM for A549 cells) for 72 h, as previously described (Crescenzi et al., 2008) . To allow the development of a fully senescent phenotype, cells were analyzed from 4 to 21 days after replating. Staining for SA-b-gal was performed as previously described (Dimri et al., 1995) .
Cell-cycle analysis Cells were fixed with 70% ethanol in phosphate-buffered saline (PBS) and routinely kept at À20 1C overnight. Cells were washed twice with PBS, resuspended in PBS, 40 mg/ml propidium iodide (Sigma), 50 mg/ml RNase DNase-free (Roche, Monza, MI, Italy) and incubated at room temperature for 20 min. 
Conditioned media
Proliferating and senescent tumor cells were rinsed with serumfree medium and incubated in OPTIMEM without serum for 48 h. Conditioned media were collected, filtered through sterile (0.2 mm) Millipore membranes and kept frozen at À80 1. The volume of conditioned medium used in each experiment was normalized for cell number.
Quantitative determination of chemokines in conditioned media Conditioned media were collected and processed as described. Determination of secreted factors in conditioned media was performed in triplicate, by using Human Cytokine 30-plex Panel (Invitrogen), according to manufacturers instructions, on two independent samples.
Cell viability
Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) and an electron-coupling reagent (phenazine methosulfate), according to the manufacturer's instructions (Promega). For MTS assay, 5 Â 10 3 senescent or proliferating cells were seeded in triplicate into 96-well plate. After 16 h, cells were treated with either anti-Fas agonistic antibody CH11 in serumfree OPTIMEM or with APO010 in complete medium. Cells were analyzed for cell viability after 24 and 48 h.
Immunofluorescence microscopy and DAPI staining Cells were grown onto glass coverslips in six-well multidishes and allowed to adhere for 16 h. To detect cell surface Fas protein, cells were fixed in 4% formaldehyde and blocked with 1% BSA in PBS-T (PBS, 0.1% Tween-20) for 15 min. Cells were incubated with anti-Fas monoclonal antibody, in a 1:200 dilution, for 1 h. Cells were washed with PBS-T and then incubated with 1:500 dilution of fluorescein-tagged secondary antibodies (Sigma). Cells were stained with 1 mg/ml DAPI (Sigma). The coverslips were mounted on a microscope slide using a 90% solution of glycerol in PBS and analyzed with a Zeiss Axioplan microscope (Zeiss, Jena, Germany) .
Flow cytometry
To analyze surface expression of death receptors, cells were detached from culture plates by incubation with 10 mM EDTA in PBS. Cell surface expression of death receptors was analyzed by flow cytometry by incubating the cells for 30 min at 4 1C with either death receptors-specific antibodies or isotype-matched control antibodies. When necessary, after two washes cells were incubated with fluorescein-tagged secondary antibodies (Sigma) for 30 min at 4 1C. Cells were analyzed immediately after staining using a CyAn ADP Flow Cytometer (DAKO Cytomation, Glostrup, Denmark) and Summit Software (DAKO Cytomation, Glostrup, Denmark). The level of surface Fas protein is expressed as the MFI minus background fluorescence of isotype-matched control.
To detect cleaved caspase-8, cells were fixed in 4% formaldehyde for 10 min at 37 1C. Cells were washed with PBS and permeabilized with 90% methanol for 30 min on ice. After washes with PBS cells were blocked with 10% fetal bovine serum in PBS-T (PBS, 0.1% Tween-20) for 15 min. Cells were washed with PBS and incubated with anti-cleaved caspase-8 (Asp391) antibody (Cell Signaling Technology, Danvers, MA, USA), in a 1:100 dilution in PBS-T, 4% fetal bovine serum for 2 h. Cells were washed and incubated with 1:200 dilution of fluorescein-tagged anti-rabbit secondary antibody (Sigma). After washes with PBS-T, cells were resuspended in PBS and were analyzed using a CyAn ADP Flow Cytometer.
Measurement of mitochondrial membrane potential were performed by staining cells with tetramethylrhodamine-ethylester (TMRE) (Invitrogen). A TMRE stock was prepared at a concentration of 10 mM in DMSO and stored at 20 1C. Cells were loaded with TMRE by incubating cells in media containing 50 nM TMRE for 30 min at 37 1C. After two washes, cells were kept at 4 1C and analyzed immediately using a CyAn ADP Flow Cytometer.
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